PanCryos
Dedicated to improving life quality for millions of people suffering from diabetes
Dedicated to improving life quality for millions of people suffering from diabetes
PanCryos, a biopharma and biotechnology startup based in Denmark, is dedicated to improving the life quality for millions of people suffering from diabetes. The company, founded in 2014, is focused on developing a next-generation stem cell-derived cell therapy called PanINSULA. Their commitment to innovation in the field of diabetes treatment has garnered attention, with their last investment of €71.43K coming from the EASME - EU Executive Agency for SMEs in August 2018. With a clear vision and a strong focus on biopharmaceutical advancements, PanCryos presents a promising investment opportunity in the healthcare sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | €71.43K | 1 | EASME - EU Executive Agency for SMEs | 01 Aug 2018 |
No recent news or press coverage available for PanCryos.
We care about your data, and we'd love to use cookies make your experience better.
